Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis by Addison, Christina L et al.
BioMed  Central
Page 1 of 15
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Overexpression of the duffy antigen receptor for chemokines 
(DARC) by NSCLC tumor cells results in increased tumor necrosis
Christina L Addison1, John A Belperio2, Marie D Burdick2 and 
Robert M Strieter*2
Address: 1Centre for Cancer Therapeutics, Ottawa Regional Cancer Centre, 503 Smyth Road, Ottawa, Ontario, K1H 1C4 Canada and 2Departments 
of Medicine, Pathology, and Pediatrics, Division of Pulmonary and Critical Care Medicine, UCLA School of Medicine, Los Angeles CA, 90024-
1922 USA
Email: Christina L Addison - Christina.Addison@orcc.on.ca; John A Belperio - jbelpario@mednet.ucla.edu; 
Marie D Burdick - mburdick@mednet.ucla.edu; Robert M Strieter* - rstrieter@mednet.ucla.edu
* Corresponding author    
Abstract
Background: The Duffy antigen receptor for chemokines (DARC) is known to be a promiscuous
chemokine receptor that binds a variety of CXC and CC chemokines in the absence of any
detectable signal transduction events. Within the CXC group of chemokines, DARC binds the
angiogenic CXC chemokines including IL-8 (CXCL8), GROα (CXCL1) and ENA-78 (CXCL5), all
of which have previously been shown to be important in non-small cell lung carcinoma (NSCLC)
tumor growth. We hypothesized that overexpression of DARC by a NSCLC tumor cell line would
result in the binding of the angiogenic ELR+ CXC chemokines by the tumor cells themselves, and
thus interfere with the stimulation of endothelial cells and induction of angiogenesis by the tumor
cell-derived angiogenic chemokines.
Results:  NSCLC tumor cells that constitutively expressed DARC were generated and their
growth characteristics were compared to control transfected cells in vitro and in vivo in SCID
animals. We found that tumors derived from DARC-expressing cells were significantly larger in size
than tumors derived from control-transfected cells. However, upon histological examination we
found that DARC-expressing tumors had significantly more necrosis and decreased tumor
cellularity, as compared to control tumors. Expression of DARC by NSCLC cells was also
associated with a decrease in tumor-associated vasculature and a reduction in metastatic potential.
Conclusions: The expression of DARC in the context of NSCLC tumors may act as a chemokine
decoy receptor and interferes with normal tumor growth and chemokine-induced tumor
neovascularization.
Background
DARC was originally identified as a blood group antigen,
and later as a coreceptor for malaria [1-3]. More recently,
it was demonstrated that DARC binds a variety of CXC
and CC chemokines [4-7]. In particular, DARC binds to
the CC chemokines monocyte chemotatic protein-1
(MCP-1; CCL2) and regulated upon activation normal T
expressed and secreted (RANTES; CCL5), and the CXC
chemokines interleukin-8 (IL-8, CXCL8), growth related
gene alpha (GRO-α, CXCL1), and neutrophil activating
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peptide-2 (NAP-2, CXCL7). Expression of DARC in vivo is
not limited to the red blood cell, and DARC expression
has been detected in endothelial cells of the kidney,
spleen and brain and in large vessel and post-capillary
venules [1,2]. It has also been detected in epithelial cells
lining the ducts of the kidney, in pulmonary alveoli [8],
and in a subset of neurons [9]. Interestingly, DARC is also
expressed in endothelial cell types in individuals who lack
expression of DARC (Duffy antigen negative) on their red
blood cells [6,10]. Therefore, the expression of DARC by
cells other than red blood cells suggests that its presence
on these cells may be important in modifying the biolog-
ical behavior of specific chemokines.
Similar to other receptors identified to date that are
known to bind chemokines, DARC is a seven-transmem-
brane receptor, however, unlike other chemokine recep-
tors, ligand binding by DARC does not induce G-protein
coupled signal transduction nor a Ca2+-flux [11]. Amino
acid alignment with other seven-transmembrane G-pro-
tein coupled receptors indicates that DARC lacks a highly
conserved DRY motif in the second intracellular loop of
the protein that is known to be associated with G-protein
signaling [12]. Despite the lack of evidence for DARC sig-
nal transduction, it has been shown in DARC-transfected
cells that DARC is internalized following ligand binding
[10]. These results have led to the hypothesis that expres-
sion of DARC on the surface of red blood cells, endothe-
lial, neuronal cells, and epithelial cells may act as a sponge
and provide a mechanism by which inflammatory chem-
okines may be removed from circulation as well as their
concentration modified in the local environment.
The members of the CXC chemokine family that bind
DARC are also known to induce angiogenic responses in
a variety of assays. The ELR+ CXC chemokines IL-8, GRO-
α and epithelial neutrophil activating protein 78 (ENA-
78, CXCL5) have all been shown to be important media-
tors of tumor-derived angiogenesis in vivo [13-19]. Neu-
tralization of ELR+ CXC chemokines in SCID mouse
models of human non-small cell lung cancer (NSCLC), as
well as human prostate cancer has demonstrated that
these molecules significantly contribute to tumor-associ-
ated neovascularization, tumor progression and metasta-
sis [17-19]. Interestingly, the angiostatic members of the
CXC chemokine family, namely the ELR- CXC chemok-
ines interferon inducible protein-10 (IP-10, CXCL10) and
monokine induced by γ-interferon (MIG, CXCL9) do not
bind to DARC [7]. Thus DARC demonstrates a disparate
activity in its ability to bind to angiogenic versus angi-
ostatic chemokines, and thus might contribute to the net
angiogenic activity within the local tumor
microenvironment.
We hypothesized that over-expression of DARC in a
tumor could lead to sequestering of angiogenic chemok-
ines from the local vascular environment and thus inhibit
tumor-associated neovascularization and tumor progres-
sion. To test this hypothesis, we chose a model of human
NSCLC, A549 cells, whose growth and metastatic poten-
tial in vivo has been previously shown to be dependent on
the production of angiogenic ELR+ CXC chemokines by
the tumor cells [17,18]. We predicted that expression of
DARC by the A549 tumor cells would lead to the binding
of angiogenic chemokines by the tumor cells themselves
and would result in the sequestering of angiogenic factors
away from the tumor-associated endothelial cells. When
A549 cells were transfected to stably over-express human
DARC, we found that over-expression of DARC by two
independently generated tumor cell clones resulted in
increased tumor size compared to control transfected
cells. Although tumor size was increased, the overexpres-
sion of DARC within the tumor was associated with
marked tumor necrosis, reduced tumor cellularity,
reduced vascularity, and impaired metastatic potential, as
compared to the control tumors. These results indicate
that DARC expression within the tumor microenviron-
ment alters the characteristics of tumor growth and inter-
feres with tumor-derived neovascularization, tumor
cellularity and metastatic potential.
Results
Generation and characterization of DARC-A549 cells
The cDNA for human DARC was generated by RT-PCR
and cloned into the pTARGET plasmid. The resulting con-
struct was used to transfect human A549 cells, and follow-
ing G418 selection, individual cell clones were isolated
and expanded. Two clones were selected for further anal-
ysis, DARC1A6 and DARC2F5. Expression of DARC in
these clones was confirmed by both northern blot detec-
tion of mRNA and by detection of surface expression of
DARC protein by FACS analysis. We detected DARC-spe-
cific message in both the DARC1A6 and DARC2F5 clones,
however no corresponding band was detected in the
pTARGET empty vector control transfected A549 cell
clone by northern blot analysis (Fig. 1). The absence of
DARC message in control cells was not due to unequal
RNA loading as the 28S and 18S message was similar in all
three RNA samples (Fig. 1). We also confirmed the expres-
sion of DARC protein in the transfected cell lines follow-
ing FACS analysis using the Fy6 monoclonal antibody
specific to human DARC (Fig. 2A). There was an increase
in the number of cells staining positive for DARC in both
DARC1A6 and DARC2F5 cells as compared to control
transfected cells. Although it would appear that only a per-
centage of transfected cells express DARC at the surface of
the cell, this is in agreement with the fact that these cells
also make IL-8 and ENA-78, therefore it is likely that
DARC is binding these chemokines in the endoplasmicBMC Cancer 2004, 4:28 http://www.biomedcentral.com/1471-2407/4/28
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reticulum or the Golgi apparatus prior to their secretion
thus preventing a proportion of DARC being expressed in
these cells from being presented on the surface of tumor
cells and thus subsequently detected by FACS. The pres-
ence of functional DARC protein on the surface of the
transfected cells was also supported by the demonstration
of increased binding of biotinylated IL-8 in DARC1A6 and
DARC2F5 cells as compared to control cells (Fig. 2B).
Taken together, these results indicate that DARC is consti-
tutively expressed at the message level and can be found
expressed at the cell surface in the DARC-transfected A549
cell clones to some degree. Furthermore, these results
demonstrate that the DARC-expressing A549 cell lines
have an increased capacity to bind an angiogenic ELR+
CXC chemokine as compared to control A549 cells, and
Northern Blot Analysis of DARC-A549 transfectants Figure 1
Northern Blot Analysis of DARC-A549 transfectants. 10 µg 
of total RNA from each cell clone was subjected to northern 
blot transfer. Expression levels of mRNA for each probe was 
densitometrically analyzed and compared to the signal 
obtained for the 28S rRNA. We observed DARC expression 
only in the A549 cells that had been transfected with a 
DARC-containing plasmid while the pTARGET control plas-
mid transfectanted appeared negative for DARC expression.
DARC-A549 transfectants have increased expression of  DARC protein and an increased ability to bind IL-8 Figure 2
DARC-A549 transfectants have increased expression of 
DARC protein and an increased ability to bind IL-8. A) The 
expression of DARC by transfected cells was determined by 
FACS analysis using the DARC-specific antibody Fy6. We 
saw no increase in the fluorescent intensity of the Control 
cell line following addition of the Fy6 antibody (solid black 
line) as compared to IgG isotype control (dotted black line). 
For both DARC1A6 (light gray line) and DARC2F5 (dark 
gray line) we observed an increase in the fluorescent inten-
sity following addition of Fy6 antibody suggesting the expres-
sion of the protein on the surface of DARC-transfected cells. 
B) We observed an increase in IL-8 binding in both 
DARC1A6 (light gray line) and DARC2F5 (dark gray line) as 
compared to the Control transfected A549 cell line (black 
line), indicating increased and functional ligand binding of IL-8 
in DARC-expressing cell lines.BMC Cancer 2004, 4:28 http://www.biomedcentral.com/1471-2407/4/28
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thus in vivo may act as a "sink" to bind soluble angiogenic
chemokines and inhibit tumor-associated angiogenesis.
We also compared the ability of DARC transfected cells to
produce the angiogenic ELR+ CXC chemokines IL-8, ENA-
78, GRO-α and GRO-γ (CXCL3) as compared to control
transfected tumor cells. Supernatants were removed from
the cells following a 72 hr incubation period and the
amount of each chemokine present in conditioned super-
natants was determined by specific ELISA for each chem-
okine. As compared to control transfected A549 cells we
saw a decrease in the amount of both IL-8 and ENA-78
present in the conditioned supernatants of the DARC-
expressing cell lines (Fig. 3A &3B). The differences in the
amount of ELR+ CXC chemokine expression between the
various cell clones was not likely a result of differences in
transcription of each message, as both DARC-expressing
A549 cell clones were found to have similar message lev-
els for IL-8 and ENA-78 as compared to control A549 cells
following northern blot analysis for specific message
(data not shown). Thus the apparent discrepancy in the
quantities of chemokines expressed by DARC-A549 cell
clones might be due to differences in the amount of chem-
okines bound in an autocrine and paracrine manner by
DARC expressed within cells as a result of binding to
DARC in the golgi or endoplasmic reticulum in DARC
expressing cells or the binding of secreted ELR+ CXC
chemokines on the surface of the DARC-transfected cells.
In addition to the DARC-binding chemokines we also
examined the amounts of two chemokines being secreted
that do not bind to DARC, namely IP-10 and MIG. We
observed low but equivalent levels of MIG being secreted
by DARC and control transfected A549 cells (0.18 ± 0.07
ng/ml for DARC1A6, 0.17 ± 0.13 ng/ml for DARC2F5 and
0.165 ± 0.11 ng/ml for control transfected A549 cells) and
could not detect any IP-10 being secreted by any of the cell
lines tested. The fact that DARC-transfected cell lines
made equivalent amounts of the non-angiogenic chemok-
ine MIG, which does not bind DARC, and that the DARC-
transfected cell clones had reduced amounts of the ang-
iogenic chemokines IL-8 and ENA-78, suggests that the
reduction in chemokines being secreted into the medium
was specific to those ELR+ CXC chemokines that bind
DARC.
Growth of DARC-A549 cells in SCID mice
Tumor growth in vivo is influenced by the dynamic equi-
librium of tumor cell growth and the ability to support
this growth through the induction of neovascularization.
Angiogenic activity is a result of the balance between ang-
iogenic vs. angiostatic factors produced and available to
endothelial cells in the local environment. In particular,
NSCLC growth has been shown to be dependent on the
ELR+ CXC chemokines and their potential interactions
with DARC, CXCR2 and glycosaminoglycans (GAGs). We
decided to determine the growth kinetics of the DARC-
expressing tumor cells in vivo in a SCID mouse model.
Since the DARC-expressing clones appeared to have slight
differences in the secreted levels of the ELR+ CXC chem-
okines as compared to the control cells, we predicted that
the DARC-expressing tumor cells would be impaired in
their ability to form tumors in vivo as a result of impaired
ability of ELR+ CXC chemokines to be secreted and form
the appropriate chemotactic gradients necessary to induce
tumor-associated angiogenesis. As can be seen in Fig. 4,
both DARC-expressing A549 cell clones readily formed
tumors in vivo, and in fact these tumors were measurably
larger than those formed by control transfected A549
cells. We observed a 2.6-fold and a 3.2-fold increase in
tumor size of DARC2F5 (3737 ± 423 mm3) and
DARC1A6 (4523 ± 532 mm3) compared to control cell
tumors (1424 ± 347 mm3) respectively (Fig. 4). Following
the 7-week duration of the experiment, animals were
euthanized and portions of the tumors were processed for
histological examination, examination of cell subtypes by
FACS analysis of single cell suspensions, and examination
of the levels of tumor-associated chemokine proteins by
ELISA of tumor homogenates. We obtained 6 mm biopsy
punch samples from each tumor and generated single cell
suspensions that were subjected to FACS analysis for
human CD49b, a marker for A549 cells, and for mouse
CD31, a marker for murine endothelial cells. We observed
a reduction in the percentage of CD49b positive cells in
both DARC transfected cell line-derived tumors as com-
pared to the control cell-derived tumors (Fig. 5). In addi-
tion, this observation was confirmed at both 3 and 4
weeks of tumor growth. Thus DARC-expressing tumors
appeared to have fewer tumor cells per unit volume of
tumor as compared to control tumors. This observation
was also confirmed following histological examination of
paraffin embedded tumor tissue. We found that although
DARC-A549 cells generated tumors that were measurably
larger than controls, these tumors had a reduction in the
number of tumor cells and an increased degree of necrosis
following examination of hemotoxylin and eosin stained
sections (Fig. 6). In an attempt to compare the degree of
tumor necrosis, we quantitated the percent necrosis from
histological sections of each tumor using morphometric
analysis and calculated the relative necrotic volume of
each tumor as described in materials and methods.
Tumors derived from both the DARC1A6 and DARC2F5
cell clones had statistically significant increases in necrotic
volume as compared to control tumors (Fig. 7, p ≤
0.0007). These data indicate that DARC-A549 derived
tumors were more necrotic and contained fewer viable
A549 tumor cells than did control tumors.
To confirm that DARC-A549 tumors contained fewer via-
ble cells than tumors derived from the control A549 cells,
we determined the percentage of apoptotic tumor cellsBMC Cancer 2004, 4:28 http://www.biomedcentral.com/1471-2407/4/28
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following TUNEL staining. We observed no significant
differences in the degree of tumor cell apoptosis as
detected by this method (22% ± 2.8% for DARC1A6, 24%
± 6% for DARC2F5 and 24% ± 5% for control). It should
be noted however, that these values were determined fol-
lowing analysis of areas containing only viable tumor and
therefore do not take into account the increased degree of
necrosis associated with the DARC-A549 tumors.
Expression of DARC in A549 tumors results in sequestering 
of IL-8 within the tumors
We hypothesized that expression of DARC by the tumor
cells themselves would result in the local sequestration of
ELR+ CXC chemokines thus preventing the formation of a
chemotactic gradient by these molecules and hence the
inability to induce productive angiogenic responses. To
examine this possibility, tumor sections were examined
for the presence of IL-8 by immunohistochemical
detection. We detected increased amounts of IL-8 in the
regions of viable tumor cells in tumors derived from
DARC1A6 (Fig. 8D) and DARC2F5 (Fig. 8F) cell lines as
compared to tumors derived from control cells (Fig. 8B).
The staining for IL-8 was specific as a similar staining pat-
tern was not observed when control pre-immune serum
was used as the primary antibody (Fig. 8A,8C and 8E for
control, DARC1A6 and DARC2F5 respectively). The IL-8
appeared to be presently mostly within tumor cells and
supports the data generated previously following analysis
Comparison of chemokine expression by DARC-A549 cells Figure 3
Comparison of chemokine expression by DARC-A549 cells. The conditioned media from each cell clone was isolated at 72 hr 
and were compared for A) IL-8, and B) ENA-78 secretion following quantitation by ELISA analysis. All bars represent the mean 
and standard error of triplicate samples.
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of the cell clones in vitro, and suggesting that reduced lev-
els of the ELR+ CXC chemokines are secreted by DARC-
transfected tumor cells. As mentioned this may be as a
result of the chemokines being bound by DARC within
tumor cells likely as a result of binding within the endo-
plasmic reticulum or golgi apparatus during production
and transport to the membrane of these proteins, or alter-
natively as a result of binding DARC at the surface of cells
in a paracrine or autocrine manner and subsequent inter-
nalization of the DARC-ligand complex as has been previ-
ously observed [10].
DARC-A549 tumors have reduced neovascularization and 
immune cell infiltration
The degree of neovascularization in DARC-A549 derived
tumors was determined following detection of mouse-
CD31 positive cells by FACS analysis of single cell tumor
suspensions generated from 6 mm biopsy punches of
each tumor. We observed a statistically significant
decrease in the number of CD31 positive endothelial cells
in tumors derived from both DARC1A6 and DARC2F5, as
compared to control tumors (Fig. 9, p = 0.0065 for
DARC1A6 compared to control tumors and p = 0.0071 for
DARC2F5 compared to control tumors). These data indi-
cated that expression of DARC by A549 tumor cells
resulted in a decrease in tumor-associated neovasculariza-
tion concomitant with an increase in tumor necrosis.
In parallel experiments, single cell tumor suspensions
were analyzed for the presence of neutrophils,
macrophages and NK cells by FACS analysis. Interestingly,
we observed statistically significant decreases in the
number of neutrophils present in tumors that expressed
DARC as compared to control tumors [5.5 ± 0.6 × 105 for
control tumors as compared to 2.0 ± 0.4 × 105  for
DARC1A6 tumors (p = 0.0017) and as compared to 2.5 ±
0.5 × 105  for DARC2F5 tumors (p = 0.0064)]. We
observed similar significant decreases in the number of
NK cells present within DARC tumors as compared to
control tumors [7.1 ± 0.4 × 105 for control tumors as com-
pared to 2.5 ± 0.6 × 105 for DARC1A6 (p = 0.0002) and as
compared to 3.3 ± 0.6 × 105 for DARC2F5 (p = 0.0009)].
Although not statistically significant, a decrease was also
observed in the number of macrophages found within
DARC tumors as compared to control tumors [5.7 ± 0.2 ×
105 for control tumors as compared to 3.4 ± 0.1 × 105 for
DARC1A6 (p = 0.32) and as compared to 2.8 ± 0.1 × 105
for DARC2F5 tumors (p = 0.25). Taken together these
data indicate an interference in the chemotactic gradients
DARC-A549 cells show enhanced tumor growth in vivo Figure 4
DARC-A549 cells show enhanced tumor growth in vivo. The 
growth of DARC-transfected A549 cells was compared in 
vivo in a SCID mouse model. Tumors were measured exter-
nally in three dimensions. Each point is a representation of 
the mean and standard error for the tumor volume of 10 
tumors. At week 7, the DARC-A549 tumors were found to 
be statistically significantly larger as compared to the control 
A549 tumors (p ≤ 0.0005).
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DARC-A549 derived tumors have reduced tumor cellularity. 
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required for the recruitment of immune cells into tissue
and further support the notion that expression of DARC
by tumor cells results in sequestration of chemokines and
modulation of chemokine responses in vivo.
DARC-A549 cells have reduced metastatic capacity
In the human NSCLC/SCID mouse model used in these
studies, we have previously found that the A549 cells will
spontaneously metastasize to the lungs beginning
approximately 4 weeks post-injection of tumor cells sub-
cutaneously [17,20]. Moreover, the magnitude of metas-
tasis of this tumor cell line has been shown to directly
correlate with the size of the primary tumor
[17,18,20,21]. To determine whether the effect of
increased necrosis and decreased primary tumor vascular-
ity was associated with metastatic potential, we next
looked at the metastatic potential of DARC2F5 as com-
pared to control tumors. We analyzed serial sections of
paraffin-embedded lung tissue from animals that had
received either control vector transfected tumor cells or
DARC2F5 tumor cells for the number and size of metas-
tases to the lung at 7 weeks post-injection. We observed a
decrease in the number of lung metastases in mice receiv-
ing DARC2F5 cells (Fig. 10A), and a statistically signifi-
cant decrease in the size of these metastases as compared
to animals that received control transfected A549 cells
(Fig. 10B, p < 0.0001). These data suggest that DARC may
interfere with tumor cell escape into the vasculature,
possibly as a result of reduced primary tumor neovascular-
ization. Furthermore, DARC expression may inhibit the
establishment and growth of micrometastases, again as a
DARC-A549 Derived tumors have significantly more necro- sis than control A549 derived tumors Figure 6
DARC-A549 Derived tumors have significantly more necro-
sis than control A549 derived tumors. Hematoxylin and 
eosin stained tumor sections from Control transfected A549 
cells (A) appear very organized and viable. In contrast sec-
tions from DARC1A6 (B) and DARC2F5 (C) derived tumors 
appear to have areas of significant necrosis and cell destruc-
tion. Fewer organized areas of viable cells are seen.
DARC-A549 Derived tumors have significantly more tumor  associated necrosis as compared to control tumors Figure 7
DARC-A549 Derived tumors have significantly more tumor 
associated necrosis as compared to control tumors. Each bar 
represents the mean and standard error of the following 
sample sizes: Control n = 47, DARC1A6 n = 100, DARC2F5 
n = 100. The p-value for DARC1A6 compared to Control 
tumors is p = 0.0007 and the p-value for DARC2F5 com-
pared to Control tumors is p < 0.0001.
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result of impaired neovascularization responses as a result
of inhibition of angiogenic ELR+ CXC chemokine activity.
Discussion
In this study, we sought to take advantage of the fact that
the Duffy antigen receptor for chemokines binds multiple
members of the ELR+ CXC family of chemokines that
induce angiogenesis in vivo. The importance of these mol-
ecules in tumor-associated neovascularization has been
previously shown in NSCLC, prostate carcinoma,
melanoma, bladder cancer, ovarian and gastric carcino-
mas [17,19,20,22-26]. As DARC has not been shown to be
associated with the induction of signal transduction
events following ligand binding, we hypothesized that the
expression of DARC within the local tumor microenviron-
ment would lead to sequestering of angiogenic CXC
chemokines, and thus compete for their binding to signal-
inducing chemokine receptors on endothelial cells. We
generated human NSCLC A549 cells that stably expressed
human DARC, and assessed their ability to form tumors
in SCID mice. Unexpectedly, we observed that the tumors
derived from DARC-expressing A549 cells had an
increased tumor volume as compared to control tumors.
This increased tumor volume observed in vivo however,
was not associated with an enhanced ability to induce
neovascularization, as tumors derived from DARC-
expressing A549 cells showed increased necrosis and a
reduced degree of neovascularization as compared to con-
trol tumors. It is also unlikely that DARC-A549 cells
expressed increased levels of CXC chemokines in vivo, as
ELISAs for IL-8, ENA-78 or GRO-α from tumor homoge-
nates at 7 weeks post-injection showed no significant dif-
ferences in these protein levels between any of the tumors
examined (data not shown). Taken together, these results
indicate that overexpression of DARC in the tumor micro-
environment likely sequesters ELR+ CXC chemokines
within cells thus interfering with the normal chemotactic
gradients that need to be formed and thus having pro-
found effects on tumor growth, neovascularization and
metastatic potential.
Our results support the hypothesis that DARC functions
as a "sink" in vivo, whereby it binds ELR+ CXC chemok-
ines and prevents them from associating with other
receptors that would lead to the induction of biological
responses, such as angiogenesis. Normally, chemokines
form a concentration gradient via a combination of solu-
ble and extracellular matrix bound protein that results in
activation and chemotaxis of endothelial and immune
cells along that gradient. We observed no differences in
DARC-A549 tumors have increased binding of IL-8 by tumor cells Figure 8
DARC-A549 tumors have increased binding of IL-8 by tumor cells. Control (A&B), DARC1A6 (C&D) and DARC2F5 (E&F) 
tumors were stained for the presence of IL-8 by immunohistochemical means using rabbit anti-human IL-8 polyclonal serum (B, 
D&F). Pre-immune rabbit serum was used as a negative control (A, C&E).BMC Cancer 2004, 4:28 http://www.biomedcentral.com/1471-2407/4/28
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the amounts of ELR+ CXC chemokines found in tumors
in vivo suggesting that DARC-expressing and control
transfected A549 cells made similar amounts of these pro-
teins, however we did observed decreased amounts of
these chemokines in conditioned cell supernatants in
vitro. This contrast is likely a reflection of the manner in
which the experiments were performed as ELISA analysis
of the levels of chemokines in vivo tumors was derived
from frozen-thawed homogenates of tumor biopsies and
thus the chemokines that would be bound to the surface
or trapped within the golgi or endoplasmic reticulum of
tumor cells would be free to be measured. In contrast, the
ELISA data generated from DARC or control transfected
tumor cells in vitro was derived on conditioned cell
supernatants only, thus would not measure the amount of
chemokine bound to the surface of cells nor sequestered
within cells due to inhibition of processing and secretion
through the endoplasmic reticulum and golgi apparatus
following binding to DARC in DARC-expressing cells.
Moreover, our immunohistochemical data from tumor
sections suggests increased amounts of IL-8 on or in
tumor cells expressing DARC as compared to control
tumors in vivo and supports the notion that perhaps the
chemotactic gradients of chemokines required to induce
appropriate neovascular responses are not formed and
instead the chemokines are sequestered by the tumor cells
themselves. We cannot however exclude the possibility
that DARC may mediate an as yet uncharacterized signal
transduction event. DARC is known to lack the highly
conserved DRY amino acid motif that interacts with G-
proteins in its second intracellular loop [12], however it
remains possible that DARC may interact with other cel-
lular receptors or membrane components and elicit spe-
cific responses to ligand binding and thus may be
contributing to the phenotype we observed via this
mechanism.
Although DARC can be detected on a variety of different
cell types, including epithelial cells, expression of DARC
in vivo is primarily localized to endothelial cells in a vari-
ety of organs and tissues. The fact that DARC is expressed
on the endothelial cell surface in people who are negative
for DARC expression on their erythrocytes [10] implies
that DARC plays an important role in modulating
endothelial cell biology. It is of interest to note that the
pattern of endothelial cells that express high levels of
DARC is similar to areas that are key in leukocyte traffick-
ing and extravasation [27-29]. This observation suggests
that DARC may be involved in the maintenance of chem-
otactic gradients across the endothelium. As mentioned
our data supports the notion that expression of DARC in
the tumor microenvironment sequesters chemokines thus
preventing the formation of the appropriate gradients to
which various cell types would migrate toward. Indeed
our results suggest that DARC-expressing tumors have an
impaired ability for NK and neutrophil extravasation into
the tumors. DARC is also strongly expressed on post-cap-
illary venules [1], the same cell type that is primarily
involved in the initiation of neovascular responses. More
recently it has been demonstrated that transgenic mice
expressing DARC under an endothelial specific promoter
have reduced angiogenic responses in the corneal micro-
pocket assay in response to MIP-2 a CC chemokine that is
also known to bind DARC [30]. Thus DARC may play a
significant role in the modulation of neovascular
responses, and our data would support the idea that
DARC plays a significant role in tumor-associated
angiogenesis.
We observed an increase in tumor necrosis and a signifi-
cant decrease in tumor-associated angiogenesis in tumors
expressing DARC which may be attributed to DARC acting
as a "sink" in vivo and disrupting chemotactic gradients
that would be required for angiogenesis to occur. More
recently it has been demonstrated that DARC knockout
mice undergo modified infiltration of leukocytes in
response to inflammatory stimuli such as lipopolysaccha-
ride suggesting that DARC may play a significant role in
DARC-A549 tumors have reduced vascularity compared to  control A549 tumors Figure 9
DARC-A549 tumors have reduced vascularity compared to 
control A549 tumors. We assessed the degree of vasculari-
zation of DARC-derived tumors by FACS analysis for murine 
CD31 as a marker of endogenous endothelial cells. For all 
samples, immunological cell types were gated out of the anal-
ysis by CD45 staining. Each bar is a representation of the 
mean and standard error following analysis of the percentage 
CD31 positive cells from 5 individual tumors for each group. 
The unpaired t-test p-values for DARC1A6 compared to 
Control tumors is p = 0.0065 and for DARC2F5 compared 
to Control tumors the p-value is p = 0.0071.
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leukocyte-endothelial cell adhesion and migration
[31,32]. Moreover, immobilization of IL-8 is required for
neutrophil emigration into tissue and it has been
suggested that this occurs via a cooperative mechanism
involving IL-8 binding to DARC and heparan sulfate [33].
Thus the decreases in immunological cell types present in
DARC tumors also supports the disruption of appropriate
chemotactic gradients along the endothelial surface as
DARC expressed on tumor cells would act as a "sink" and
sequester chemotactic chemokines within the tumor
itself. This may partially explain the increase in size of
DARC expressing tumors as normally dying tumor cells in
necrotic areas would be removed by infiltrating immune
cells leading to resolution of the necrosis and this process
might not occur if these cells cannot extravasate into the
tumor space, leading to increases in the necrotic areas and
hence overall size of the tumor. Impaired infiltration of
immune cells might also contribute to the reduced neo-
vascularization observed in DARC-expressing tumors as it
has been shown that the presence of macrophages may
contribute to tumor growth and progression and induc-
tion of tumor neovascularization [34,35]. As we observed
DARC2F5 cells have impaired metastatic capabilities Figure 10
DARC2F5 cells have impaired metastatic capabilities. The lungs from 5 tumor-bearing mice from each group were sectioned in 
their entirety. A) The number of metastatic lesions was counted in 7 different sections a minimum of 60 µm apart for each lung 
(40× magnification). Each bar represents the mean and standard error of 35 counts for each group. The p-value is 0.1476. B) 
The size of each metastatic lesion was determined by morphometric analysis using NIH image analysis software (400× magnifi-
cation). Each bar represents the mean and standard deviation. For Control n = 534, and for DARC2F5 n = 361. The p-value is 
p < 0.0001.
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a slight reduction in the number of tumor-associated mac-
rophages in DARC-A549 tumors as compared to control
tumors it remains possible that in addition to DARC
directly binding angiogenic chemokines and preventing
them from directly affecting the neovasculature, that
reduction in infiltrating immune cells may also contribute
to the reduced neovascularization associated with DARC-
A549 tumor growth.
As mentioned, we hypothesized that DARC expression by
the tumor cells would bind the angiogenic chemokines
and sequester them from endothelial cells, thus prevent-
ing endothelial cell chemotaxis and tumor-associated
angiogenesis. The lack of tumor-associated angiogenic
activity would lead to significant increases in tumor
necrosis, which is what was observed in our DARC-A549
generated tumors. The lack of endothelial cell recruitment
into the tumor may partly explain why we observed a
reduction in the spontaneous metastasis of the DARC-
A549 tumors, since metastasis is thought to occur by
tumor cell invasion of the vasculature. The ability of
DARC to inhibit neovascular responses could result in the
inhibition of the establishment and growth of microme-
tastases. This hypothesis is supported by our data that
DARC2F5 cells have fewer and significantly smaller meta-
static nodules in the lung, as compared to the control
A549 cells.
Conclusions
In summary, we have shown that expression of DARC in
the tumor microenvironment results in altered tumor
growth associated with a reduction in neovascularization
and an increase in tumor necrosis. While the mechanism
behind this altered phenotype is as yet unclear it appears
that expression of DARC by the tumor cells alters the
tumor-endothelial cell relationship, perhaps by
sequestering angiogenic factors and acting as a chemokine
sink as has been previously suggested. Thus expression of
DARC by human tumors may be correlated with a less
aggressive and metastatic phenotype in vivo. Our results
clearly indicate the important role of DARC in endothelial
cell biology and support the need for further study of the
function of this receptor in various cell types.
Materials and methods
Reagents
Polyclonal rabbit anti-human IL-8 sera was produced by
immunization of rabbits with IL-8, (Peprotech, Rocky
Hill, NJ) in multiple intradermal sites with complete Fre-
und's adjuvant. This antibody has been previously well
characterized for its neutralizing capacity [17]. The IL-8
anti-serum specificity has been confirmed by Western blot
analysis against recombinant human IL-8 and was found
to neutralize 30 ng of IL-8 at a dilution of 1:1000 [17].
Furthermore, in a sandwich ELISA, this antibody is
specific for IL-8 without cross-reactivity to a panel of 12
other recombinant human cytokines or the murine chem-
okines KC and MIP-2 [17].
Human cell lines
The A549 human adenocarcinoma cell line (ATCC CCL
185) was purchased from the American Type Culture Col-
lection (Rockville MD). A549 cells were maintained in
RPMI 1640 medium supplemented with 1 mM
glutamine, 25 mM Hepes buffer, 100 U/ml penicillin, 100
ng/ml streptomycin and 10% fetal bovine serum (all from
Whitaker Biomedical Products, Whitaker CA).
Generation of stably transfected NSCLC cell lines
The cDNA for human DARC was amplified by RT-PCR
from total RNA isolated from K562-DARC cells that had
been stably transfected to express DARC using the follow-
ing primer pair: Forward – 5' CAT CTG AAT TCC TGC
AGA GAC CTT GTT C 3' and Reverse – 5' AAA GGA TCC
GTC TAG ACT TTA ATT CAG GTT CAG 3'. RT-PCR was
performed using the Access RT-PCR kit according to the
manufacturer's directions (Promega Corp., Madison WI).
The reverse transcriptase reaction was performed at 48°C
for 45 min, followed by denaturation at 94°C for 2 min.
PCR amplification was then performed using the follow-
ing cycle conditions: 94°C for 1 min, 56°C for 1 min,
68°C for 2 min for a total of 40 cycles, followed by a 7
min extension cycle at 68°C. The resulting 1.2 kb DNA
band was gel purified using the Wizard PCR purification
kit and cloned into the pTARGET mammalian expression
plasmid system (both from Promega Corp., Madison WI).
A549 cells were transfected with varying quantities of
plasmid DNA using the calcium phosphate-mediated
transfection technique [36]. Following transfection, cells
were grown in the presence of 400 µg/ml of G418
(Geneticin, Gibco BRL, Grand Island, NY), and G418
resistant colonies were isolated and expanded in culture.
One empty pTARGET control vector transfected line was
chosen for further comparisons and from herein will be
referred to as "control". Two independently generated
DARC-expressing A549 cell lines were chosen for further
analysis, DARC1A6 and DARC2F5.
ELISA analysis
The quantity of IL-8, ENA-78, and GRO-α, GRO-γ, IP-10
and MIG present in conditioned cell supernatants was
determined by specific ELISA, using a modification of the
double ligand method as previously described [13,37].
Briefly, flat-bottomed 96-well microtiter plates were
coated with 50 µl/well of specific polyclonal rabbit anti-
CXC chemokine antibodies (1 µg/ml in 0.6 M NaCl, 0.26
M H3BO3, 0.08 N NaOH, pH 9.6) for 24 hr at 4°C, and
then washed with PBS pH 7.5 plus 0.05% Tween-20
(wash buffer). Plates were blocked with 2% BSA in PBS for
1 h at 37°C and then washed three times with washBMC Cancer 2004, 4:28 http://www.biomedcentral.com/1471-2407/4/28
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buffer. 50 µl of sample (1:10 and neat) was added and the
plates were incubated at 37°C for 1 h. Plates were washed
three times, 50 µl of appropriate biotinylated polyclonal
anti-CXC chemokine antibodies (3.5 ng/µl in PBS, pH
7.5, 0.05% Tween-20 and 2% FBS) were added, and plates
were incubated at 37°C for 45 min. Plates were washed
three times, streptavidin-peroxidase conjugate was added,
and the plates were incubated for 30 min at 37°C. Plates
were washed again and 100 µl of 3, 3', 5, 5'-tetramethyl-
benzidine (TMB) chromogenic substrate was added.
Plates were incubated at room temperature to the desired
extinction and the reactions were terminated by the addi-
tion of 100 µl/well of 1 M H3PO4. Plates were read at 450
nm in an automated microtiter plate reader and the
amount of CXC chemokine present was determined by
interpolation of a standard curve generated by known
amounts of recombinant CXC chemokine protein. The
sensitivity for the specific chemokine ELISAs was >50 pg/
ml and these assays failed to cross-react with a panel of
other known cytokines and chemokines.
Northern blot analysis
Expression of DARC was detected at the message level by
Northern blot analysis. Total RNA was extracted from cells
in Trizol (Gibco BRL, Rockville MD), and 10 µg of RNA
was subjected to formaldehyde agarose gel electrophore-
sis. The RNA was then transferred overnight by capillary
transfer in 10 × SSC to nylon membranes (Roche,
Indianapolis IN) and the membranes were subsequently
UV cross-linked. For mRNA detection of the northern
blot, dioxygenin (DIG)-labeled probes were generated
following random priming reactions of a gel purified
cDNA fragment using the DIG-High Prime kit according
to the manufacturer's recommendations (Roche,
Indianapolis IN). Hybridization and detection of the
DIG-labeled probes was performed according to the man-
ufacturer's directions (Roche, Indianapolis IN). Ethidium
bromide staining of the blot for 28S and 18S rRNA was
used as a control to ensure equal loading of the gel.
Detection of DARC on transfected cells
DARC protein was detected on transfected cells by FACS
analysis. Briefly, cells were removed from flasks in 1 mM
ice cold EDTA in PBS and then incubated at 4°C for 1 hr
with 5 µg/ml Fy6 monoclonal antibody to human DARC
or with isotype control antibody. Following two washes
with ice-cold PBS containing 0.2% FBS, cells were incu-
bated with FITC-conjugated anti-mouse antibody and
incubated for an additional 1 hr at 4°C. Cells were again
washed two times, and were then fixed with 2% parafor-
maldehyde prior to FACS analysis.
Binding of IL-8 by DARC transfected cells
Transfected cells were removed from flasks following
incubation in 1 mM ice cold EDTA in PBS. Cells were then
incubated in the presence of biotinylated IL-8, and bound
ligand was detected using FITC-conjugated streptavidin
according to the manufacturer's protocol (Pharmingen,
San Diego CA). Bound IL-8 ligand was then detected by
FACS analysis.
Human NSCLC-SCID mouse chimeras
Six to eight week old CB-17 SCID mice were injected sub-
cutaneously (sc) in each flank with 1 × 106 A549 NSCLC
cells in 100 µl. On a weekly basis once palpable tumors
were visible, tumors were measured in three dimensions
with engineer's calipers. Tumor volume was calculated
using the equation axbxc where 'a' is the longest diameter,
'b' is its perpendicular, and 'c' is the depth of the tumor. At
3, 4 and 7 weeks post-tumor cell injection, animals were
euthanized by ketamine overdose, the tumors were
removed and measured as described above, and a portion
was fixed in 4% paraformaldehyde for histological analy-
ses. Another portion of the tumor was snap frozen and
stored at -70°C for generation of protein extracts. Total
protein extracts were generated by subsequent homogeni-
zation and sonication in Complete™ antiprotease buffer
(Roche Molecular Diagnostics, Indianapolis, IN) and fil-
tration through a 1.2 µm filter. Protein concentration was
determined using the BCA Protein Assay Kit (Pierce, Rock-
ford IL), and specific chemokine ELISAs were performed
as described above. All chemokine concentrations were
normalized to total protein.
FACS analysis
Two 6 mm tumor punches were minced in 5 ml of Dis-
pase® (Becton Dickinson, San Jose, CA) solution and incu-
bated with agitation for 1 h in a 37°C water bath. Cells
were further separated by repeatedly aspirating the cell
suspension through a 20 ml syringe, and filtration
through gauze. Cells were then pelleted at 600 × g for 10
min, resuspended in sterile water for 30 s to lyse
remaining red blood cells, and washed in 1 × PBS. Cells
were counted and transferred at a concentration of 5 × 106
cells/ml to fluorescent antibody solution (1% FA buffer,
1% FBS, and 0.1% sodium azide), and maintained at 4°C
for the remainder of the staining procedure. 100 µl of the
cell suspension was labeled with FITC-conjugated anti-
mouse CD31 to detect mouse endothelial cells, or with
PE-conjugated anti-human CD49b to detect human A549
tumor cells (both from Pharmingen, San Diego CA). All
samples were simultaneously incubated with Tri-color-
conjugated anti-mouse CD45 to detect endogenous
immunological cell types that were then gated out. These
results are therefore presented as the percentage of posi-
tive cells following the exclusion of murine CD45 positive
cell populations. Immune cells were also detected in
parallel samples using PE-conjugated anti-mouse DX5
(for NK cells, Pharmingen, San Diego CA), FITC-conju-
gated Ly-6G (for neutrophils, Pharmingen, San DiegoBMC Cancer 2004, 4:28 http://www.biomedcentral.com/1471-2407/4/28
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CA), and FITC-conjugated Moma-2 (for macrophages,
Serotec, Raleigh NC). The unbound antibody was washed
with FA buffer and the cell suspension subsequently ana-
lyzed by FACS.
In situ detection of apoptotic tumor cells
For each tumor group, three paraffin-embedded tumor
sections were taken a minimum of 60 µm apart from 5 dif-
ferent tumors (n = 15 per group). For detection of apop-
tosis, DNA fragmentation was determined using the In
situ cell death detection kit (Roche, Indianapolis IN). The
percentage of cells staining positive by TUNEL was deter-
mined in 10 random fields of view at 200× magnification.
Fields of view that were completely necrotic were excluded
for these purposes.
Immunohistochemical detection of IL-8
Tumor sections were subjected to immunohistochemical
staining for IL-8 as previously described [17,38]. Briefly,
tumor sections were incubated in a 1:500 dilution of rab-
bit anti-human IL-8 serum or rabbit pre-immune serum.
Primary antibody was detected with biotinylated goat
anti-rabbit antibodies followed by incubation with
streptavidin-conjugated HRP and colorimetric detection
with 3,3'-diaminobenzidine (DAB) (all detection reagents
from Vector Laboratories, Burlingame CA). Sections were
counterstained in Mayer's hematoxylin.
Statistical and morphometric analyses
All statistical analysis of data was performed using the
Statview 4.5 software program (SAS Institute Inc., Cary
NC). Groups of data that appeared statistically different
were compared by Students t test for comparison of
means, and were considered statistically significant if p-
values of <0.05 were obtained. The Mann-Whitney U test
was used to compare groups of observations that did not
appear normally distributed, and were considered statisti-
cally significant if p-values of <0.05 were obtained. For
analysis of lung metastases and necrotic areas, morpho-
metric analysis was performed on at least 16 separate
hematoxylin and eosin stained sections taken 60 µm apart
from each of 5 different animals under 200× magnifica-
tion. An Olympus BH-2 microscope coupled to a Sony
3CCD camera was used to capture images that were then
analyzed for total area of metastatic lesions using the NIH
Image 1.55 software. For determination of tumor necro-
sis, the average percentage of necrotic area per high power
field (200×) for each tumor was determined by
morphometric analysis, and this number was then multi-
plied by the tumor volume yielding the average necrotic
volume for each tumor.
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